SpringWorks shares rise on FDA nod for GOMEKLI
Shares of SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) climbed 2.7%, building on a previous gain of 2%, following the FDA ...
Pharmaceutical Technology4h
Travere takes rare disease kidney drug to FDA despite failed trial
Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.
Upcoming Patent Loss of Jakafi Highlights Portfolio Risks; Downgrading Incyte's Moat to None
We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...
Blockbuster weight-loss drugs flood grey market, used without supervision: ‘This trend is triggering paralysis of gut,’ warn doctors
Tirzepatide, found in Mounjaro and Zepbound, mimics both GIP and GLP-1 hormones to activate insulin production. Semaglutide, ...
Pharm Exec19h
FDA Approves AbbVie’s Emblaveo for Complicated Intra-Abdominal Infections
Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...
clinicaltrialsarena22h
Boehringer seeks approval of lung disease drug after second Phase III success
Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.